Patent application number | Description | Published |
20090280160 | PHENYLEPHRINE PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS FOR TRANSMUCOSAL ABSORPTION - Pharmaceutical compositions comprising phenylephrine or a pharmaceutically acceptable salt thereof and methods for administering the pharmaceutical compositions wherein the composition is formulated for systemic absorption of phenylephrine that avoids first pass metabolism. The compositions of the invention are formulated to be applied to oral mucosa of an animal to allow for enhanced systemic delivery of therapeutically active form of phenylephrine. | 11-12-2009 |
20100081672 | PH SENSITIVE MATRIX FORMULATION - The present invention provides formulations of therapeutic agents that benefit from a prolonged time of controlled release in the stomach and upper gastrointestinal (GI) tract, and from an enhanced drug exposure to the upper GI tract. The formulations of the invention comprise a therapeutic agent and one or more pH sensitive polymers that are designed for accelerated hydration, expansion, disintegration and dissolution at the higher pH of the upper GI tract, thereby, ensuring that any therapeutic agent that has not been released in the stomach is released in the upper GI tract, thus maximizing absorption of therapeutic agent that has a window of absorption located at the upper GI tract. | 04-01-2010 |
20110038925 | INTRAVENOUS FORMULATIONS OF NEUROKININ-1 ANTAGONISTS - Pharmaceutical compositions for intravenous administration comprising the compound of Formula I | 02-17-2011 |
20120022032 | CORTICOSTEROID COMPOSITIONS AND METHODS OF TREATMENTS THEREOF - This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and can be used for the treatment of diseases of the upper and/or lower airway passages. | 01-26-2012 |
20130096053 | POSACONAZOLE INTRAVENOUS SOLUTION FORMULATIONS STABILIZED BY SUBSTITUTED BETA-CYCLODEXTRIN - The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified β-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties. | 04-18-2013 |
20150265715 | POSACONAZOLE INTRAVENOUS SOLUTION FORMULATIONS STABILIZED BY SUBSTITUTED BETA-CYCLODEXTRIN - The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified β-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties. | 09-24-2015 |
20150290147 | PHENYLEPHRINE PHARMACEUTICAL FORMULATIONS AND COMPOSITIONS FOR COLONIC ABOSORPTION - The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s). The pharmaceutical composition can further comprise one or more additional therapeutically active agents selected from one or more of the group consisting of antihistamines, analgesics, anti-pyretics, and non-steroidal anti-inflammatory agents. The invention also discloses methods of administering phenylephrine via the colon, thereby increasing the bioavailable amount of therapeutically active unconjugated phenylephrine relative to the total phenylephrine in the plasma. | 10-15-2015 |
20160024092 | INTRAVENOUS FORMULATIONS OF NEUROKININ-1 ANTAGONISTS - Pharmaceutical compositions for intravenous administration comprising the compound of Formula I | 01-28-2016 |
Patent application number | Description | Published |
20090095472 | WELL TREATMENT FLUID COMPOSITIONS AND METHODS OF USE THAT INCLUDE A DELAYED RELEASE PERCARBONATE FORMULATION - A well treatment fluid and method of use includes water, at least one hydratable polymer, an optional crosslinking agent, and a delayed release percarbonate formulation effective to reduce initial viscosity of the fluid after a period of time. Also disclosed are processes for fracturing a subterranean formation. | 04-16-2009 |
20100218950 | BIOCIDE FOR WELL STIMULATION AND TREATMENT FLUIDS - A well stimulation and or treatment fluid that includes water, other additives, and a biocide consisting of 3,5-dimethyl-1,3,5-thiadiazinane-2-thione in an amount effective to inhibit bacterial growth and minimize antagonistic reactions between the biocide and other additives. Also disclosed are well injection compositions, stimulations, squeezing, waterflood, packing, cement compositions, and methods for cementing. | 09-02-2010 |
20110278008 | WELL TREATMENT FLUID COMPOSITIONS AND METHODS OF USE THAT INCLUDE A DELAYED RELEASE PERCARBONATE FORMULATION - A well treatment fluid and method of use includes water, at least one hydratable polymer, an optional crosslinking agent, and a delayed release percarbonate formulation effective to reduce initial viscosity of the fluid after a period of time. Also disclosed are processes for fracturing a subterranean formation. | 11-17-2011 |
20130165352 | Well Treatment Fluid Compositions and Methods of Use That Include a Delayed Release Percarbonate Formulation - A well treatment fluid and method of use includes water, at least one hydratable polymer, an optional crosslinking agent, and a delayed release percarbonate formulation effective to reduce initial viscosity of the fluid after a period of time. Also disclosed are processes for fracturing a subterranean formation. | 06-27-2013 |
Patent application number | Description | Published |
20130248760 | PARTICLE FOR GASIFICATION CONTAINING A CELLULOSE CORE WITH A COATING OF LIGNIN - A biomass composition of matter to be used in a torrefaction process or a biomass gasification reaction is described. The biomass in a particle form is created in a pretreatment step that occurs prior to the torrefaction process or the biomass gasification reaction. A bulk structure of the biomass is 1) stripped apart to at least partially separate an outer layer of lignin in the biomass from the cellulose fibers, 2) internally blown apart to create fragments of the fiber bundle, and 3) any combination of the two in the pretreatment step. The biomass in particle form has a length to thickness aspect ratio on average of less than 300 to 1, a thickness on average of less than 100 microns thick and a length on average of less than 3000 microns. | 09-26-2013 |
20130248767 | PRETREATMENT OF BIOMASS USING THERMO MECHANICAL METHODS BEFORE GASIFICATION - An integrated plant generates syngas from biomass, where the integrated plant includes a Thermo Mechanical Pulping (TMP) process, a biomass gasifier, a methanol synthesis process, and a liquid fuel generation process. Biomass is received as a feedstock in the TMP process. The biomass is pre-treated in the TMP process for subsequent supply to the biomass gasifier by using a combination of heat, pressure, moisture, and mechanical agitation that are applied to the biomass to make the biomass into a pulp form. The TMP process breaks down a bulk structure of the received biomass, at least in part, by applying steam to degrade bonds between lignin and hemi-cellulose from cellulose fibers of the biomass. Next, the broken down particles of the biomass are reacted in a biomass gasification reaction at a temperature of greater than 700 degrees C. to create syngas components, which are fed to a methanol synthesis process. | 09-26-2013 |